Search

FIND and SystemOne announce collaboration for connected diagnostics

  • Initial priorities to include diagnostics for TB, hepatitis C, HIV and Ebola

5 December 2016 – Cape Town, South Africa – FIND (Geneva, Switzerland) and SystemOne (Boston, USA and Johannesburg, South Africa) have announced a collaboration to advance the connectivity of diagnostics in low- and middle-income countries, initially prioritizing the areas of tuberculosis, hepatitis C, HIV and Ebola.

The collaboration will combine SystemOne’s substantial capacity in providing IT and data solutions for diagnostics, including successful implementation of GxAlert in over 30 countries, SystemOne’s connectivity suite based on the AspectTM platform and FIND’s expertise as a non-profit increasing access to affordable diagnostics for low- and middle-income countries, including delivery of all eight WHO-endorsed diagnostic tools for TB in the past decade.

“SystemOne welcomes this collaboration with FIND as we continue to scale up the Aspect Connectivity Platform to multiple diseases across different manufacturers’ diagnostic devices,” said Chris Macek, CEO of SystemOne. “With installations in over 30 countries and growing, SystemOne will continue to focus on the needs of Ministries of Health, working with FIND to streamline the integration of connectivity into the diagnostics space in a sustainable and responsible way.”

FIND and SystemOne will work together to ensure that connected diagnostics drive programmatic improvements. One of several planned projects focuses on ensuring that selected diagnostic tools for hepatitis C virus can be integrated with Aspect to enable improved linkages from diagnosis to treatment and care.

“We see this collaboration as an opportunity to fast-track key improvements in connected diagnostics, which hold a great deal of promise for improving the links from diagnosis to treatment and supporting better programme monitoring,” said Dr Catharina Boehme, FIND CEO. “Meeting new global diagnostic connectivity targets for TB and other diseases requires a new way of thinking about diagnostic tools.”

The World Health Organization recently issued ambitious new connectivity targets for laboratory strengthening under the End TB Strategy. These include that all sites using WHO-recommended rapid diagnostic tests should be transmitting results electronically to clinicians and information management systems, and monitoring key performance indicators using data connectivity solutions by 2020.

For more information, please contact:
info@systemone.id Julie Archer, Senior Communications Officer, FIND
julie.archer@finddx.org
+41 22 749 29 33 (desk) / +41 79 830 63 64 (mob)

About SystemOne
Founded in 2012, SystemOne focuses on producing game-changing data-based solutions for connected diagnostic devices.  SystemOne’s products, GxAlert™ (Tuberculosis) and Aspect™ (Multi-disease), are medical device connectivity software that collect and share data to:

  1. Reduce patient time-to-treatment by immediately transmitting disease results to clinicians and patients,
  2. Save millions of dollars in supply chain waste—experienced as stockouts or overstock/expiring consumables—by monitoring and improving instrument utilization and right-sizing consumable purchases,
  3. Provide real-time disease-surveillance monitoring across instruments, across diseases, and across countries.

The company’s new connectivity software, Aspect, addresses additional infectious diseases, including Ebola, HIV, Malaria, Hepatitis C and more on a host of diagnostic devices from Abbott, Alere, Becton Dickinson, Cepheid, Humastar, Sysmex, Roche, and others.

About FIND 
FIND, established in 2003, is a global non-profit dedicated to accelerating the development, evaluation and use of high-quality, affordable diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, non-malarial fevers and infectious diseases with outbreak potential such as Ebola. Over the last decade, FIND has partnered in the delivery of 14 new diagnostic tools, including eight for tuberculosis, and created an enabling environment for numerous others through the provision of specimen banks, reagent development and better market visibility.

FIND also supports better access to new diagnostics through implementation, quality assurance and lab strengthening work. FIND has more than 200 partners globally, including research institutes and laboratories, health ministries and national disease control programmes, commercial partners, clinical trial sites, and bilateral and multilateral organizations, especially WHO.